Literature DB >> 21174625

Pharmacometabonomics as an effector for personalized medicine.

Jeremy K Nicholson1, Ian D Wilson, John C Lindon.   

Abstract

This article introduces and reviews the concept of pharmacometabonomics, with recent experimental exemplifications of the approach being described and discussed. Pharmacometabonomics seeks to predict the response of an individual to a stimulus (e.g., drug, toxin, surgery, nutrition and so on) prior to the stimulus or other perturbation. It is an integral part of top-down systems biology which aims to improve understanding of phenotypic differences and the impact of beneficial and pathological interventions. The pharmacometabonomic concept is also integral to the understanding of mammalian-gut microbiome cometabolic interactions and their consequences, including the impact on disease and therapy. Although the subject is only at an early stage and requires further exemplification and validation, the approach has major implications for improved efficiency in drug discovery efforts, for example, by enabling more careful selection of animals in preclinical studies, for better stratification of patients in drug clinical trials and for individualized therapies. It could also find application in population-wide large cohort studies and in studies of nutrition where it would allow the elucidation of health risk factors and provide easily measured surrogate biomarkers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21174625     DOI: 10.2217/pgs.10.157

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  38 in total

Review 1.  Clinical metabolomics: the next stage of clinical biochemistry.

Authors:  Angelo D'Alessandro; Bruno Giardina; Federica Gevi; Anna Maria Timperio; Lello Zolla
Journal:  Blood Transfus       Date:  2012-05       Impact factor: 3.443

2.  Metabolomics technology and bioinformatics for precision medicine.

Authors:  Rajeev K Azad; Vladimir Shulaev
Journal:  Brief Bioinform       Date:  2019-11-27       Impact factor: 11.622

Review 3.  Promise of personalized omics to precision medicine.

Authors:  Rui Chen; Michael Snyder
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2012-11-26

4.  Enhanced phase II detoxification contributes to beneficial effects of dietary restriction as revealed by multi-platform metabolomics studies.

Authors:  He Wen; Hye-Ji Yang; Yong Jin An; Joon Mee Kim; Dae Hyun Lee; Xing Jin; Sung-Woo Park; Kyung-Jin Min; Sunghyouk Park
Journal:  Mol Cell Proteomics       Date:  2012-12-09       Impact factor: 5.911

5.  Integration analysis of metabolites and single nucleotide polymorphisms improves the prediction of drug response of celecoxib.

Authors:  Xiaoqing Xing; Pengcheng Ma; Qing Huang; Xiemin Qi; Bingjie Zou; Jun Wei; Lei Tao; Lingjun Li; Guohua Zhou; Qinxin Song
Journal:  Metabolomics       Date:  2020-03-14       Impact factor: 4.290

6.  Pilot analysis of the plasma metabolite profiles associated with emphysematous Chronic Obstructive Pulmonary Disease phenotype.

Authors:  Mikell Paige; Marie D Burdick; Suhyon Kim; Junrui Xu; Jae K Lee; Y Michael Shim
Journal:  Biochem Biophys Res Commun       Date:  2011-09-08       Impact factor: 3.575

7.  Genetic determinants of metabolism in health and disease: from biochemical genetics to genome-wide associations.

Authors:  Steven L Robinette; Elaine Holmes; Jeremy K Nicholson; Marc E Dumas
Journal:  Genome Med       Date:  2012-04-30       Impact factor: 11.117

8.  Bioinformatics Tools for Mass Spectroscopy-Based Metabolomic Data Processing and Analysis.

Authors:  Masahiro Sugimoto; Masato Kawakami; Martin Robert; Tomoyoshi Soga; Masaru Tomita
Journal:  Curr Bioinform       Date:  2012-03       Impact factor: 3.543

Review 9.  Translational research in infectious disease: current paradigms and challenges ahead.

Authors:  Judith M Fontana; Elizabeth Alexander; Mirella Salvatore
Journal:  Transl Res       Date:  2012-01-15       Impact factor: 7.012

10.  Metabonomic profiling of serum and urine by (1)H NMR-based spectroscopy discriminates patients with chronic obstructive pulmonary disease and healthy individuals.

Authors:  Lingling Wang; Yufu Tang; Shuo Liu; Shitao Mao; Yuan Ling; Dan Liu; Xiaoyu He; Xiaoge Wang
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.